Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study
January 18, 2021
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
Key Capital partners and supports business initiatives with the potential to make a difference to our Health, Wealth, or Environment.
Ticker Symbol: KCPC
Exchange: OTC Pink
Signature Stock Transfer Inc.
2632 Coachlight Ct.
Plano, TX, 75093
972-612-4120
signaturestocktransfer@msn.com
Peter Boonen, Chairman
Peter Boonen, Chairman
GET
In Touch
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
NEW YORK, NY, January 6, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis.
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine.